Cargando…
Extracellular Vesicles: An Emerging Nanoplatform for Cancer Therapy
Extracellular vesicles (EVs) are cell-derived membrane particles that represent an endogenous mechanism for cell-to-cell communication. Since discovering that EVs have multiple advantages over currently available delivery platforms, such as their ability to overcome natural barriers, intrinsic cell...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897670/ https://www.ncbi.nlm.nih.gov/pubmed/33628730 http://dx.doi.org/10.3389/fonc.2020.606906 |
_version_ | 1783653714044649472 |
---|---|
author | Ma, Yifan Dong, Shiyan Li, Xuefeng Kim, Betty Y. S. Yang, Zhaogang Jiang, Wen |
author_facet | Ma, Yifan Dong, Shiyan Li, Xuefeng Kim, Betty Y. S. Yang, Zhaogang Jiang, Wen |
author_sort | Ma, Yifan |
collection | PubMed |
description | Extracellular vesicles (EVs) are cell-derived membrane particles that represent an endogenous mechanism for cell-to-cell communication. Since discovering that EVs have multiple advantages over currently available delivery platforms, such as their ability to overcome natural barriers, intrinsic cell targeting properties, and circulation stability, the potential use of EVs as therapeutic nanoplatforms for cancer studies has attracted considerable interest. To fully elucidate EVs’ therapeutic function for treating cancer, all current knowledge about cellular uptake and trafficking of EVs will be initially reviewed. In order to further improve EVs as anticancer therapeutics, engineering strategies for cancer therapy have been widely explored in the last decade, along with other cancer therapies. However, therapeutic applications of EVs as drug delivery systems have been limited because of immunological concerns, lack of methods to scale EV production, and efficient drug loading. We will review and discuss recent progress and remaining challenges in developing EVs as a delivery nanoplatform for cancer therapy. |
format | Online Article Text |
id | pubmed-7897670 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78976702021-02-23 Extracellular Vesicles: An Emerging Nanoplatform for Cancer Therapy Ma, Yifan Dong, Shiyan Li, Xuefeng Kim, Betty Y. S. Yang, Zhaogang Jiang, Wen Front Oncol Oncology Extracellular vesicles (EVs) are cell-derived membrane particles that represent an endogenous mechanism for cell-to-cell communication. Since discovering that EVs have multiple advantages over currently available delivery platforms, such as their ability to overcome natural barriers, intrinsic cell targeting properties, and circulation stability, the potential use of EVs as therapeutic nanoplatforms for cancer studies has attracted considerable interest. To fully elucidate EVs’ therapeutic function for treating cancer, all current knowledge about cellular uptake and trafficking of EVs will be initially reviewed. In order to further improve EVs as anticancer therapeutics, engineering strategies for cancer therapy have been widely explored in the last decade, along with other cancer therapies. However, therapeutic applications of EVs as drug delivery systems have been limited because of immunological concerns, lack of methods to scale EV production, and efficient drug loading. We will review and discuss recent progress and remaining challenges in developing EVs as a delivery nanoplatform for cancer therapy. Frontiers Media S.A. 2021-02-08 /pmc/articles/PMC7897670/ /pubmed/33628730 http://dx.doi.org/10.3389/fonc.2020.606906 Text en Copyright © 2021 Ma, Dong, Li, Kim, Yang and Jiang http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Ma, Yifan Dong, Shiyan Li, Xuefeng Kim, Betty Y. S. Yang, Zhaogang Jiang, Wen Extracellular Vesicles: An Emerging Nanoplatform for Cancer Therapy |
title | Extracellular Vesicles: An Emerging Nanoplatform for Cancer Therapy |
title_full | Extracellular Vesicles: An Emerging Nanoplatform for Cancer Therapy |
title_fullStr | Extracellular Vesicles: An Emerging Nanoplatform for Cancer Therapy |
title_full_unstemmed | Extracellular Vesicles: An Emerging Nanoplatform for Cancer Therapy |
title_short | Extracellular Vesicles: An Emerging Nanoplatform for Cancer Therapy |
title_sort | extracellular vesicles: an emerging nanoplatform for cancer therapy |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897670/ https://www.ncbi.nlm.nih.gov/pubmed/33628730 http://dx.doi.org/10.3389/fonc.2020.606906 |
work_keys_str_mv | AT mayifan extracellularvesiclesanemergingnanoplatformforcancertherapy AT dongshiyan extracellularvesiclesanemergingnanoplatformforcancertherapy AT lixuefeng extracellularvesiclesanemergingnanoplatformforcancertherapy AT kimbettyys extracellularvesiclesanemergingnanoplatformforcancertherapy AT yangzhaogang extracellularvesiclesanemergingnanoplatformforcancertherapy AT jiangwen extracellularvesiclesanemergingnanoplatformforcancertherapy |